Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Idhifa Enasidenib Acute myeloid leukemia (AML) Do not reimburse Complete
Tramacet Tramadol hydrochloride /acetaminophen Acute pain Do not list Complete
Trisenox Arsenic Trioxide Acute Promyelocytic Leukemia Reimburse Complete
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Active
Verzenio abemaciclib Adjuvant treatment of HR-positive, HER2-negative early breast cancer Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Advanced Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Ibrance Resubmission Palbociclib Advanced breast cancer Reimburse with clinical criteria and/or conditions Complete
Libtayo Cemiplimab Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Reimburse with clinical criteria and/or conditions Complete
Keytruda and Lenvima pembrolizumab and lenvatinib Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete
Keytruda pembrolizumab Advanced endometrial cancer Reimburse with clinical criteria and/or conditions Complete